Education
About Us
Working with TipRanks
Follow Us
Bioxytran (BIXT)
:BIXT
BIXT Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.06 - $0.23
Previous CloseN/A
Volume481.75K
Average Volume (3M)163.66K
Market Cap
$12.45M
Enterprise Value$11.96M
Total Cash (Recent Filing)$0.00
Total Debt (Recent Filing)$853.00K
Price to Earnings (P/E)―
Beta-1.34
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding88,992,240
10 Day Avg. Volume264,049
30 Day Avg. Volume163,658
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio-65.47
Enterprise Value/Market Cap0.96
Enterprise Value/Revenue-76.63
Enterprise Value/Gross Profit-429.85
Enterprise Value/Ebitda-1.21
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Bioxytran News
PremiumCompany Announcements
Bioxytran Delays 10-K Filing Due to Audit
PremiumCompany Announcements
Bioxytran Expands Portfolio with NDPD Pharma AcquisitionOptions Prices
Currently, No data available
---
Ownership Overview
33.25% Insiders
―
Mutual Funds
― Other Institutional Investors
66.75% Public Companies and
Individual Investors
BIXT FAQ
What was Bioxytran ’s price range in the past 12 months?
Bioxytran lowest stock price was $0.06 and its highest was $0.23 in the past 12 months.
What is Bioxytran ’s market cap?
Bioxytran ’s market cap is $12.45M.
When is Bioxytran ’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Bioxytran ’s earnings last quarter?
Currently, no data Available
Is Bioxytran overvalued?
According to Wall Street analysts Bioxytran ’s price is currently Overvalued.
Does Bioxytran pay dividends?
Bioxytran does not currently pay dividends.
What is Bioxytran ’s EPS estimate?
Bioxytran ’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Bioxytran have?
Bioxytran has 88,992,240 shares outstanding.
What happened to Bioxytran ’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Bioxytran ?
Currently, no hedge funds are holding shares in BIXT
Company Description
Bioxytran
Bioxytran, Inc., a clinical stage pharmaceutical company, focuses on the development, manufacture, and commercialization of therapeutic drugs to address hypoxia in humans. The company's lead drug candidate is BXT-25, an oxygen-carrying small molecule consisting of bovine hemoglobin stabilized with a co-polymer for use in the treatment of hypoxic conditions in the brain resulting from stroke, and hypoxic conditions in wounds to prevent necrosis and to promote healing. It is also developing ProLectin-Rx, a polysaccharide derived from pectin that binds to, and blocks the activity of galectin-1, a type of galectin for treatment of mild to moderate cases of Covid-19. The company was incorporated in 2008 and is headquartered in Newton, Massachusetts.
Technical Analysis
Traws Pharma
―
Affimed
―
BioRestorative Therapies
―
Spruce Biosciences
―
Sensei Biotherapeutics
―